Alternative Polyadenylation Reprogramming of MORC2 Induced by NUDT21 Loss Promotes KIRC Carcinogenesis

Overview

Journal JCI Insight

Specialties Biomedical Engineering
General Medicine

Date 2023 Sep 22

PMID 37737260

Authors

Yuqin Tan

Tong Zheng

Zijun Su

Min Chen

Suxiang Chen

Rui Zhang

Ruojiao Wang

Ke Li

Ning Na

Affiliations

Soon will be listed here.

Abstract

Alternative polyadenylation (APA), a posttranscriptional mechanism of gene expression via determination of 3'UTR length, has an emerging role in carcinogenesis. Although abundant APA reprogramming is found in kidney renal clear cell carcinoma (KIRC), which is one of the major malignancies, whether APA functions in KIRC remains unknown. Herein, we found that chromatin modifier MORC2 gained oncogenic potential in KIRC among the genes with APA reprogramming, and moreover, its oncogenic potential was enhanced by 3'UTR shortening through stabilization of MORC2 mRNA. MORC2 was found to function in KIRC by downregulating tumor suppressor DAPK1 via DNA methylation. Mechanistically, MORC2 recruited DNMT3A to facilitate hypermethylation of the DAPK1 promoter, which was strengthened by 3'UTR shortening of MORC2. Furthermore, loss of APA regulator NUDT21, which was induced by DNMT3B-mediated promoter methylation, was identified as responsible for 3'UTR shortening of MORC2 in KIRC. Additionally, NUDT21 was confirmed to act as a tumor suppressor mainly depending on downregulation of MORC2. Finally, we designed an antisense oligonucleotide (ASO) to enhance NUDT21 expression and validated its antitumor effect in vivo and in vitro. This study uncovers the DNMT3B/NUDT21/APA/MORC2/DAPK1 regulatory axis in KIRC, disclosing the role of APA in KIRC and the crosstalk between DNA methylation and APA.

Citing Articles

RNA-Based Therapies in Kidney Diseases.

Hu L, Jin T, Zhang N, Ding J, Li L J Inflamm Res. 2025; 18:3143-3160.

PMID: 40059951 PMC: 11890006. DOI: 10.2147/JIR.S505252.

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.

uORF-targeting steric block antisense oligonucleotides do not reproducibly increase RNASEH1 expression.

Ahlskog N, Svrzikapa N, Abuhamdah R, Kye M, Jad Y, Feng N Mol Ther Nucleic Acids. 2025; 36(1):102406.

PMID: 39759875 PMC: 11697566. DOI: 10.1016/j.omtn.2024.102406.

Translational regulation of PKD1 by evolutionarily conserved upstream open reading frames.

Chen L, Gao X, Liu X, Zhu Y, Wang D RNA Biol. 2025; 22(1):1-12.

PMID: 39757590 PMC: 11810096. DOI: 10.1080/15476286.2024.2448387.

Biological functions and molecular mechanisms of MORC2 in human diseases.

Zhao X, Miao J Mol Cells. 2024; 48(1):100166.

PMID: 39637946 PMC: 11731582. DOI: 10.1016/j.mocell.2024.100166.

References

Chang J, Yeh H, Yong J . Alternative Polyadenylation in Human Diseases. Endocrinol Metab (Seoul). 2017; 32(4):413-421. PMC: 5744726. DOI: 10.3803/EnM.2017.32.4.413. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Christoph F, Hinz S, Weikert S, Kempkensteffen C, Schostak M, Miller K . Comparative promoter methylation analysis of p53 target genes in urogenital cancers. Urol Int. 2008; 80(4):398-404. DOI: 10.1159/000132698. View

Zi H, He S, Leng X, Xu X, Huang Q, Weng H . Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019. Mil Med Res. 2021; 8(1):60. PMC: 8611255. DOI: 10.1186/s40779-021-00354-z. View

Liu J, Shao Y, He Y, Ning K, Cui X, Liu F . MORC2 promotes development of an aggressive colorectal cancer phenotype through inhibition of NDRG1. Cancer Sci. 2018; 110(1):135-146. PMC: 6317918. DOI: 10.1111/cas.13863. View

Erson-Bensan A . Alternative polyadenylation and RNA-binding proteins. J Mol Endocrinol. 2016; 57(2):F29-34. DOI: 10.1530/JME-16-0070. View

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

Zheng T, Lu M, Wang T, Zhang C, Du X . NRBE3 promotes metastasis of breast cancer by down-regulating E-cadherin expression. Biochim Biophys Acta Mol Cell Res. 2018; 1865(12):1869-1877. DOI: 10.1016/j.bbamcr.2018.09.003. View

Thivierge C, Tseng H, Mayya V, Lussier C, Gravel S, Duchaine T . Alternative polyadenylation confers Pten mRNAs stability and resistance to microRNAs. Nucleic Acids Res. 2018; 46(19):10340-10352. PMC: 6212768. DOI: 10.1093/nar/gky666. View

10.

Phatak P, Donahue J . Biotinylated Micro-RNA Pull Down Assay for Identifying miRNA Targets. Bio Protoc. 2021; 7(9):e2253. PMC: 8410240. DOI: 10.21769/BioProtoc.2253. View

11.

Chandrashekar D, Karthikeyan S, Korla P, Patel H, Shovon A, Athar M . UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022; 25:18-27. PMC: 8788199. DOI: 10.1016/j.neo.2022.01.001. View

12.

Mcdermott D, Regan M, Clark J, Flaherty L, Weiss G, Logan T . Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 23(1):133-41. DOI: 10.1200/JCO.2005.03.206. View

13.

Rinaldi C, Wood M . Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2017; 14(1):9-21. DOI: 10.1038/nrneurol.2017.148. View

14.

Tan S, Li H, Zhang W, Shao Y, Liu Y, Guan H . NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. Oncogene. 2018; 37(35):4887-4900. DOI: 10.1038/s41388-018-0280-6. View

15.

Ren F, Zhang N, Zhang L, Miller E, Pu J . Alternative Polyadenylation: a new frontier in post transcriptional regulation. Biomark Res. 2020; 8(1):67. PMC: 7690165. DOI: 10.1186/s40364-020-00249-6. View

16.

Gruber A, Zavolan M . Alternative cleavage and polyadenylation in health and disease. Nat Rev Genet. 2019; 20(10):599-614. DOI: 10.1038/s41576-019-0145-z. View

17.

Xia Z, Donehower L, Cooper T, Neilson J, Wheeler D, Wagner E . Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. Nat Commun. 2014; 5:5274. PMC: 4467577. DOI: 10.1038/ncomms6274. View

18.

Christoph F, Hinz S, Kempkensteffen C, Schostak M, Schrader M, Miller K . mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype. J Urol. 2007; 178(6):2655-9. DOI: 10.1016/j.juro.2007.07.116. View

19.

Su Y, Yu T, Wang Y, Huang X, Wei X . Circular RNA circDNM3OS Functions as a miR-145-5p Sponge to Accelerate Cholangiocarcinoma Growth and Glutamine Metabolism by Upregulating MORC2. Onco Targets Ther. 2021; 14:1117-1129. PMC: 7898209. DOI: 10.2147/OTT.S289241. View

20.

Nanavaty V, Abrash E, Hong C, Park S, Fink E, Li Z . DNA Methylation Regulates Alternative Polyadenylation via CTCF and the Cohesin Complex. Mol Cell. 2020; 78(4):752-764.e6. PMC: 7245569. DOI: 10.1016/j.molcel.2020.03.024. View